MarketInOut Stock Screener Log In | Sign Up
 

Beam Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 05/22/2026
Beam Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,745.85 mln
Float87.97 mln
Earnings Date08/11/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-0.5
Highly suspicious

1-Year Forecast

51.07
Transformational upside

Relative Strength

5 / 100
Severely lagging

Debt / Equity

0.22
Very low leverage

ROE

-5.87
Negative

Business Description

Beam Therapeutics is a Cambridge, Massachusetts-based biotech company founded in 2017 that develops targeted gene-editing treatments for patients with serious inherited conditions. The company is advancing a pipeline of therapies for blood disorders and genetic diseases, including treatments for sickle cell disease, alpha-1 antitrypsin deficiency, and several rare liver conditions. Beam also works with partners such as Pfizer, Verve Therapeutics, and Orbital Therapeutics to expand its gene-editing research across the liver, muscle, and nervous system.

Key Fundamentals

EPS-0.49
ROE-5.87
RPS1.59
ROIC-118
ROA-4.56
EBITDA, mln-349
EV / EBITDA-6.77
EV / EBIT-6.36
Revenue, mln164
EV / Revenue14.42

Financial Strength

Altman Z-Score5.6
Piotroski F-Score 3 / 9
Beneish M-Score-0.5
1-Year Target Price51.07
Short Ratio9.71
Short % of Float31.53

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 2.54% 74 / 100   
1 Month -5.04% 17 / 100   
2 Months 2.58% 58 / 100   
6 Months 36.51% 90 / 100   
1 Year 66.32% 89 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us